Clinical trial
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
NCT00313599 · University of California, San Francisco, Other · Completed
Key facts
| NCT number | NCT00313599 |
|---|---|
| Title | Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane™ in Patients With Advanced Solid Tumors |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Esophageal Cancer, Extragonadal Germ Cell Tumor, Gastric Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer |
| Intervention type | Drug |
| Interventions | lapatinib, paclitaxel |
| Enrollment | 28 |
| Start date | Feb 1, 2006 |
| Primary completion | Dec 1, 2013 |
| Completion | Dec 1, 2013 |
| First posted | Apr 12, 2006 |
| Last update posted | Jul 2, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: